Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

WALTHAM, Mass., March 5 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has successfully completed a $38 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P. This announcement follows the initiation of a Phase 1/2 human clinical study of its lead product, PRT-201, in patients with end stage renal disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, Proteon further bolstered its cash reserves by entering into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201 with a potential secondary right to a global license under pre-agreed conditions. Including the initial acquisition payment plus potential additional regulatory milestone payments, the deal with Novartis could exceed $550 million.

The Series B financing includes new investors, the MPM Bio IV NVS Strategic Fund L.P. and the Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon's original angel investors. Concurrent with the investment, Proteon also announced the addition of Dr. Steven St. Peter, Managing Director of MPM Capital, to the Proteon Therapeutics Board of Directors.

"Patients with kidney failure endure great suffering and frequent hospitalization due to vascular access complications. If successful, PRT-201 may improve medical outcomes and lower the associated cost of care," said Timothy P. Noyes, President and CEO of Proteon. "We greatly appreciate the continued support of our existing venture and angel investors, and we are excited to welcome MPM and Vectis as new investors." The combination of the Novartis option agreement and the closing of the Series B financing will allow Proteon to develop PRT-201 through Phase 2.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... CSM, a leading ... as Vice President of Finance. Morse has an extensive background in financial management and ... the CSM team. In his new role, Morse will oversee all financial areas of ...
(Date:7/7/2015)... ... 2015 , ... The Pistoia Alliance, a global, not-for-profit alliance ... R&D, has attracted a number of new members from across the industry. , ... as a Core member, and DNAnexus and Tessella as Participating members. Genexyx and ...
(Date:7/6/2015)... ... 06, 2015 , ... A study by a multidisciplinary research ... fungi adapt through genetic modifications to fight back against the effects of medication ... These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal ...
(Date:7/6/2015)... 2015  Approximately 1% of the population inherits a ... These individuals are three times more likely to develop ... of the nation,s leading medical journals by researchers from ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... roseola (also known as "sixth disease") and occasional seizures ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Pistoia Alliance Continues to Attract New Members 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... ... test alternative using innovative laser technology has been installed at the fastest ... China has acquired Sepha ’s ‘BlisterScan’ machines for non-destructive leak testing on a ... ...
... ... dedicated to peptides and related products. Wide range of new peptide synthesis reagents and ... high-quality peptides. , ... Melbourne, Australia (PRWEB) October 22, 2009 -- Mimotopes Pty Ltd, a subsidiary of Commonwealth ...
... ... and Ralph M. Lerner named Senior Vice President of Commercial Development , ... Marlborough, Mass. (Vocus) October 23, ... technology turns biomass into cellulosic ethanol, has welcomed Kevin F. McLaughlin and Ralph M. ...
Cached Biology Technology:Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 3Mimotopes Launches Online Peptide Superstore 2Mimotopes Launches Online Peptide Superstore 3Cellulosic Biofuels Leader Qteros Adds Key Positions 2Cellulosic Biofuels Leader Qteros Adds Key Positions 3
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... supplies are scarce in many areas of the United States, ... often regarded as the clean-burning energy source of the future ... previously thought. Their study appeared in ACS, journal Environmental ... out in the study that annual bioethanol production in the ...
... challenges the increasingly popular belief that smoking marijuana is ... Canada are reporting that smoking marijuana, like smoking tobacco, ... for the Aug. 17 issue of ACS, Chemical ... Maertens and colleagues note that people often view marijuana ...
... As the world,s environment ministers, government officials, diplomats ... Copenhagen in December 2009 to unite in the battle ... political deals the world has ever seen, the increasingly ... an article published today, 5 August, 2009, in IOP ...
Cached Biology News:Climate change poker: The barriers which are preventing a global agreement 2
b6-2A12...
Request Info...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... be able to handle larger sample volumes, automate ... as interface with telemetry systems. The AccuSampler ... dogs, pigs, and primates. The system may ... the computer can be located outside the animal ...
Biology Products: